Humacyte, Inc. (HUMA) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 27, 2026 7:00 AM EDT- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -Â
- Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia -
- Submitted of a Marketing Authorization Application with the Israel Ministry of Health -
- U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels -
- Major milestone upcoming:... More
